We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

GE Healthcare Launches Capto™ ImpRes Ion Exchangers for Purification of Recombinant Proteins

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
The first Capto ImpRes products to be launched are Capto SP ImpRes and Capto Q ImpRes, strong cation and strong anion exchangers, respectively, that enable high throughput, high resolution polishing, and flexibility in process design.

Capto ImpRes media are based on a rigid high-flow agarose matrix that allows the use of high flow rates and higher bed heights, providing biopharmaceutical manufacturers with the possibility to reduce cycle times and maintain or reduce column equipment footprint, thus contributing to driving improvements in process economics.

“The extension of the Capto platform with Capto ImpRes ion exchangers demonstrates our commitment to supporting biopharmaceutical manufacturers with the most modern tools to improve their processes in terms of throughput, productivity, and economy,” said Dr Nigel Darby, Vice President, Biotechnologies, GE Healthcare. “Capto ImpRes media have been designed to meet the throughput and high resolution needs of intermediate purification and polishing.”

Capto ImpRes media are available in several convenient formats, including Predictor™ 96-well filter plates and prepacked HiTrap™ and HiScreen™ columns to support all stages of biopharmaceutical development and manufacture. As part of the GE Healthcare BioProcess™ media platform, Capto ImpRes ion exchangers are manufactured under validated production methods, backed up with Regulatory Support Files, and have Secure Supply routines in place.